Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 17/20 | 0.43 |
| ▸ | NPY1R | P25929 | 10/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.43 |
| ▸ | NPY2R | P49146 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30435145 | 0.90 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL29566169 | 0.88 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL30148458 | 0.86 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL30302903 | 0.85 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL31064825 | 0.84 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL29799968 | 0.83 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL30148421 | 0.83 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL30658141 | 0.83 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL30945402 | 0.83 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL30456493 | 0.83 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0561876-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA. | SMITHKLINE BEECHAM PLC (GB) | 1993-09-29 | — | — | EP | disclosed |
| EP-0561905-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF MACULAR DEGENERATION | SMITHKLINE BEECHAM PLC (GB) | 1993-09-29 | — | — | EP | disclosed |
| EP-0561878-A1 | USE OF ANGIOTENSIN II ANTAGONIST IN THE TREATMENT OF INFARCTION | SMITHKLINE BEECHAM PLC (GB) | 1993-09-29 | — | — | EP | disclosed |
| EP-0561939-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM PLC (GB) | 1993-09-29 | — | — | EP | disclosed |
| EP-0561901-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY | SMITHKLINE BEECHAM PLC (GB) | 1993-09-29 | — | — | EP | disclosed |
| EP-0561979-A1 | USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF ANGINA PECTORIS | SMITHKLINE BEECHAM PLC (GB) | 1993-09-29 | — | — | EP | disclosed |
| EP-0561895-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS | SMITHKLINE BEECHAM PLC (GB) | 1993-09-29 | — | — | EP | disclosed |
| EP-0561977-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF HEMORRAGIC STROKE | SMITHKLINE BEECHAM PLC (GB) | 1993-09-29 | — | — | EP | disclosed |
| EP-0561896-A1 | USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION | SMITHKLINE BEECHAM PLC (GB) | 1993-09-29 | — | — | EP | disclosed |